Taysha Gene Therapies (TSHA) Q2 2024 earnings summary

Executive summary

• TSHA-102 clinical trials for Rett syndrome demonstrated encouraging safety and efficacy in both adult and pediatric cohorts, with no serious adverse events or dose-limiting toxicities reported to date.

• The program expanded into Canada, and the first patient was dosed in the high-dose cohort for the adolescent/adult trial, with IDMC approval for further dosing in both high-dose cohorts.

• The company deprioritized or discontinued other programs, focusing solely on TSHA-102 for Rett syndrome.

• Completed a $76.8 million public offering, strengthening the financial position and extending the cash runway into Q4 2026.

• Focus remains on clinical trial execution, data collection, and regulatory engagement to advance development plans.

Financial highlights

• Research and development expenses were $15.1 million for Q2 2024, down from $19.8 million in Q2 2023, mainly due to a prior milestone payment.

• General and administrative expenses rose to $7.3 million from $6.0 million year-over-year, driven by higher stock-based compensation and consulting fees.

• Net loss for Q2 2024 was $20.9 million ($0.09 per share), compared to $24.6 million ($0.38 per share) in Q2 2023.

• Cash and cash equivalents totaled $172.7 million as of June 30, 2024.

• Revenue for Q2 2024 was $1.1 million, down from $2.4 million in Q2 2023, from Rett R&D activities under the Astellas agreement.

Outlook and guidance

• Current cash resources are expected to fund operations into Q4 2026.

• Safety and efficacy data from both low- and high-dose cohorts in both trials are expected in the first half of 2025.

• Dosing of additional patients in high-dose cohorts for both adolescent/adult and pediatric trials is scheduled for Q3 2024.

• Ongoing regulatory engagement includes an upcoming Type B meeting under RMAT designation to align on trial design and endpoints for pivotal studies.

• Anticipates increased R&D expenses for Rett clinical trials and manufacturing; expects to require additional capital for future operations and commercialization.